Search

everythinglearnresearchcommunity

for

Search:↓

JAK inhibitors can be safely used for alopecia areata in patients with latent hepatitis B or stable tuberculosis with proper monitoring.

Bendamustine combined with tucidinostat may effectively treat adult T-cell leukemia.

Upadacitinib is effective and safe for treating severe alopecia areata in teens.

Sorafenib can cause facial acne-like eruptions, which improve after reducing the dose or stopping the drug.

Janus kinase inhibitors may effectively treat severe alopecia areata unresponsive to other treatments.

Glibenclamide slows breast cancer cell growth by stopping cell division.

Ritlecitinib is effective and safe for hair regrowth in Asian patients with alopecia areata.

Ritlecitinib is more effective and cost-efficient than baricitinib for severe alopecia areata.

Baricitinib helps with early hair regrowth in people with alopecia areata.

CTP-543 effectively promotes hair regrowth in adults with moderate to severe alopecia areata.

Using CDK inhibitors on rats showed a reduction in chemotherapy-caused hair loss, but later experiments could not repeat these results.

Tofacitinib helps hair regrowth in alopecia areata but relapse is common after stopping treatment.

JAK inhibitors can be safely used in alopecia areata patients with latent hepatitis B or tuberculosis, with proper monitoring.

A patient with Alopecia Areata had complete hair regrowth after using the drug baricitinib.

The paper concludes that the new medication baricitinib needs further testing in a more diverse group of patients with alopecia areata.

TICE salvage chemotherapy is effective for treating germ-cell tumors with poor prognosis.

Tofacitinib is effective for severe alopecia areata, similar to oral betamethasone.

Tofacitinib effectively treated a woman's severe symptoms from a rare autoimmune condition.

JAK inhibitors show promise for treating skin conditions like eczema, hair loss, and psoriasis.

Ritlecitinib is more effective and cheaper than baricitinib for treating severe alopecia areata.

Baricitinib is effective and safe for treating severe alopecia areata, promoting significant hair regrowth.

Tofacitinib effectively promotes hair regrowth in children with alopecia areata, but more research on long-term safety is needed.

M50054 may help treat hepatitis and hair loss from chemotherapy.

Baricitinib helped a woman with severe hair loss regrow almost all her hair without side effects.

Ritlecitinib is effective and safe for treating severe alopecia areata in people aged 12 and older.

Brepocitinib 30mg is most effective for moderate-to-severe alopecia areata, but ritlecitinib 50mg may offer a better balance of safety and effectiveness.

Ruxolitinib effectively and safely regrows hair in alopecia patients.

Upadacitinib effectively treated a patient with multiple inflammatory conditions.

Baricitinib may reactivate trichilemmal cysts in people with a history of these cysts.